Hexaware Technologies announced on December 13, 2025, that it has filed a motion to dismiss an infringement claim. The claim was filed by Natsoft Corporation and Updraft LLC in the United States District Court, Northern District of Illinois, Eastern Division. The initial communication regarding this matter was dated October 1, 2025. Information about this will be available on Hexaware’s website.

Infringement Claim Update

Hexaware Technologies has taken action regarding the infringement claim filed by Natsoft Corporation and Updraft LLC. The company officially filed a motion to dismiss the case as of December 13, 2025.

Legal Proceedings

The motion has been submitted to the United States District Court for the Northern District of Illinois, Eastern Division. This follows an earlier communication on October 1, 2025, regarding the infringement claim. Further details are available on Hexaware’s official website.

Source: BSE

IndiGo announced that it operated over 2,000 flights for the second consecutive day, demonstrating continued operational normalization and stability. On December 12, 2025, the airline operated over 2,050 flights with only two cancellations. IndiGo ensures all 138 operational destinations are connected and on-time performance is consistently normal. The airline continues to operate according to its revised schedule.

Operational Normalization

IndiGo reported that it is set to operate over 2,050 flights on December 13, 2025, marking the second consecutive day with over 2,000 flights operated. This achievement demonstrates the airline’s ongoing operational stability following adjustments to its schedule as per government directives.

Flight Statistics

The airline confirms its network of 138 operational destinations remains connected. IndiGo also highlights consistently normal on-time performance that meet internal standards.

Recent Flight Operations

On December 12, 2025, IndiGo operated over 2,050 flights, with only two cancellations due to technical issues. Affected customers were immediately reaccommodated on alternate flights.

Operational Data Summary

• December 8, 2025: Over 1,700 flights operated with 1 cancellation
• December 9, 2025: Over 1,800 flights operated with 0 cancellations
• December 10, 2025: Over 1,900 flights operated with 2 cancellations
• December 11, 2025: Over 1,950 flights operated with 4 cancellations
• December 12, 2025: Over 2,050 flights operated with 2 cancellations
• December 13, 2025: Over 2,050 flights expected

Passenger Assurance

IndiGo urges passengers to rely on official information and avoid misinformation regarding mass cancellations. The airline has coordinated with airport partners to display updated flight schedules on terminal screens to prevent confusion. IndiGo serves over 3.25 lakh customers daily.

Source: BSE

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has announced a change to its website address. The company’s website has been updated from www.suvenpharm.com to www.cohance.com, effective December 13, 2025. This change reflects the company’s rebranding and should be noted for all future communications and information access.

Website Address Update

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited, has officially changed its website address. Effective December 13, 2025, the company’s new website is www.cohance.com.

Reason for Change

The website address change is a direct result of the company’s name change from “Suven Pharmaceuticals Limited” to “Cohance Lifesciences Limited”. This rebranding is now reflected in the updated website address. All stakeholders are advised to update their records accordingly.

Key Information

The old website address, www.suvenpharm.com, has been replaced. For all information, updates, and communications, please visit www.cohance.com.

Source: BSE

Biocon Biologics has reached a settlement and license agreement with Regeneron and Bayer, enabling the commercialization of its biosimilar Aflibercept in Europe and worldwide. This agreement allows Biocon Biologics to launch Yesafili®, its biosimilar Aflibercept, across global markets, with launches planned for the United Kingdom in January 2026 and other settled countries by March 2026 or earlier. The settlement dismisses all pending litigation.

Global Commercialization Agreement

Biocon Biologics Ltd (BBL) has announced a new settlement and license agreement with Regeneron and Bayer, clearing the path for the global commercialization of its biosimilar Aflibercept. This agreement builds upon a previous settlement covering the United States and Canada.

Yesafili® Launch Timeline

The agreement enables Biocon Biologics to launch Yesafili®, a biosimilar Aflibercept (40mg/ml), in all countries. Plans are in place to launch in the United Kingdom in January 2026, with subsequent launches in other settled countries slated for March 2026 or earlier, under certain circumstances. The specific terms of the settlement remain confidential.

Biosimilar Aflibercept Details

YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor used to treat multiple ophthalmology conditions.

Executive Commentary

Shreehas Tambe, CEO & Managing Director of Biocon Biologics, stated, “This settlement paves the way for Biocon Biologics to make available our biosimilar Aflibercept globally. This milestone expands our presence in the ophthalmology therapeutic area as we work closely with healthcare systems to increase access to patients everywhere.”

Regulatory Approvals

YESAFILI has secured approval from both the European Commission (EC) and the Medicines & Healthcare products Regulatory Agency (MHRA).

Previous Market Entries

Biocon Biologics previously secured market entry for its biosimilar Aflibercept for the U.S. in April 2025, and also launched in Canada with market entry secured in March 2024.

Targeted Conditions

YESAFILI is intended for the treatment of several eye disorders, including neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular edema secondary to retinal vein occlusion, visual impairment due to diabetic macular edema (DME), and visual impairment due to myopic choroidal neovascularisation (myopic CNV).

Source: BSE

Novelis Inc., a wholly-owned subsidiary of Hindalco Industries, has announced the selection of Ernst & Young LLP (EY) as its independent registered public accounting firm. The change is for the fiscal year ending March 31, 2028, and is subject to required regulatory compliance. Novelis has filed a Form 8-K with the U.S. Securities and Exchange Commission regarding this change. The filing can be accessed via a provided link.

Change in Accountant

Novelis Inc., a wholly owned subsidiary of Hindalco Industries Limited, has announced a change in its certifying accountant. Ernst & Young LLP (EY) has been selected to serve as the company’s independent registered public accounting firm.

Fiscal Year Details

This selection of Ernst & Young LLP (“EY”) applies to the fiscal year ending March 31, 2028. The appointment is subject to the completion of required regulatory compliances and procedures.

SEC Filing Information

In accordance with the change, Novelis Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission. Details of the filing can be accessed online.

Company Websites

Additional details regarding this announcement will be available on the company websites: www.hindalco.com and www.novelis.com.

Source: BSE

PVR INOX has announced the opening of 5 new screens at Inorbit Mall, Cyberabad, Hyderabad, transforming the cinema into an 11-screen superplex. The Superplex features 3 premium formats — Luxe, PXL, and 4DX. This launch makes PVR INOX the largest multiplex network with 1772 screens across 355 properties in 111 cities (India and Sri Lanka).

Hyderabad Superplex Launch

PVR INOX has expanded its presence in Hyderabad with the launch of 5 new screens at Inorbit Mall, Cyberabad. This expansion transforms the existing cinema into an 11-screen superplex, offering a variety of viewing experiences.

Superplex Features

The newly upgraded superplex includes 3 premium formats: Luxe, PXL, and 4DX, alongside mainstream screens. These formats are designed to cater to diverse audiences, including families, young adults, and working professionals, with enhanced visuals, sound, and comfort.

PXL and 4DX Highlights

The superplex features Telangana’s first PXL screen, equipped with a 55-foot-wide screen, RGB laser projection, Dolby Atmos sound, and recliner seating. The 4DX screen, the third in Hyderabad, offers motion seats and special effects like wind, fog, scent, water, and snow to enhance the viewing experience.

Network Expansion

With this launch, PVR INOX now operates the largest multiplex network, comprising 1772 screens across 355 properties in 111 cities throughout India and Sri Lanka, solidifying its position in the cinema exhibition industry.

Seating Capacity

The 11-screen Superplex houses a total of 1,368 seats, which includes 210 PXL seats, 107 Luxe seats, 104 4DX seats, and 947 mainstream seats.

Source: BSE

Finolex Cables has announced the resignation of its Compliance Officer, Mrs. Gayatri Kulkarni, effective December 12, 2025, at 5:15 pm. Her resignation, tendered on November 13, 2025, is due to personal reasons. The company has accepted the resignation and relieved her from her duties in accordance with company policy.

Compliance Officer Transition

Mrs. Gayatri Kulkarni, previously serving as Assistant Company Secretary & Compliance Officer at Finolex Cables, has resigned from her position. The resignation was tendered on November 13, 2025, and has been accepted by the company.

Effective Date of Resignation

The company confirms that Mrs. Kulkarni will be relieved from her duties effective December 12, 2025, at 5:15 pm. The decision is attributed to personal reasons, as stated in the initial resignation letter.

Source: BSE

PTC India has formed a joint venture with NLC India Renewables Limited (NIRL) to explore opportunities in green energy projects across India. The collaboration aims to develop projects up to 2000 MW, including solar, wind, hydro, and battery storage systems. PTC India will hold a 26% stake in the joint venture, while NLC India Renewables Limited will hold 74%.

Strategic Alliance for Green Energy

PTC India announced a Joint Venture Agreement with NLC India Renewables Limited (NIRL) on December 12, 2025, to jointly pursue opportunities in the Green Energy sector. The partnership aims to leverage the strengths of both companies to develop a portfolio of renewable energy projects across India.

Projected Development and Scope

The joint venture will focus on the development of Green Energy Projects with a cumulative capacity of up to 2000 MW. This includes a diverse range of renewable energy sources, such as solar, wind, hydro, and battery storage systems, implemented on a pan-India basis. The execution of these projects will be subject to the fulfillment of conditions outlined in the joint venture agreement and the receipt of necessary regulatory approvals.

Equity and Governance Structure

As part of the agreement, NLC India Renewables Limited will hold a 74% shareholding in the joint venture, while PTC India will hold the remaining 26%. The agreement also includes provisions for the appointment of Nominee Directors on the Board of the JV Company, ensuring appropriate governance and strategic oversight. Both parties have the Right of First Refusal and Tag along rights.

Source: BSE

SJVN Green Energy Limited (SGEL), a subsidiary of SJVN, has achieved commercial operation of 100.56 MW capacity of its 1,000 MW Bikaner Solar Power Project as of December 12, 2025. The project has a total cumulative commissioned capacity of 830.70 MW, and the remaining capacity is expected to be commissioned soon.

Bikaner Solar Project Milestone

SJVN’s subsidiary, SJVN Green Energy Limited (SGEL), has announced the commencement of commercial operations for a portion of its ambitious Bikaner Solar Power Project. As of December 12, 2025, 100.56 MW of the project has been successfully commissioned, marking a significant step forward in the renewable energy initiative.

Current Capacity and Future Outlook

With the commissioning of this latest capacity, the Bikaner Solar Power Project now boasts a total cumulative commissioned capacity of 830.70 MW out of the total 1,000 MW. The company anticipates commissioning the remaining capacity shortly, further solidifying its commitment to sustainable energy generation.

Source: BSE